A study found that patients with both hematologic malignancies and advanced melanoma being treated with immune checkpoint inhibitors experienced significantly worse melanoma-related outcomes compared with patients without hematological malignancies.

Faith E. Davies, MD, provides an update on treatment options for patients with multiple myeloma in early relapse at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.

Alice J Chen, PhD, found that delays affected access to CAR-T treatments and treatment effectiveness among patients with refractory and relapsed aggressive blood cancer.